Related Experiment Video
Updated: Jan 14, 2026
Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
Assessing the therapeutic potential of Tirzepatide in modulating inflammatory responses and mitigating acute
Razan Alawaji1,2, Mohamed S Abdel-Bakky1, Hussein M Ali1,3
1Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia.
Background:
Acute pancreatitis (AP) is a severe inflammation of the pancreas, marked by elevated enzyme levels, cellular inflammation, and necrosis. Recent studies emphasize the critical role of inflammation in AP progression. Tirzepatide, a multi-target agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, has demonstrated notable anti-inflammatory and metabolic benefits.
Methods:
This study explores the therapeutic potential of Tirzepatide in pancreatitis induced by L-arginine in rats, focusing on enzymatic markers, cytokine profiles, oxidative stress, and histological outcomes. Over 27 days, rats were distributed into Control, Tirzepatide, L-Arginine, and L-Arginine + Tirzepatide groups, with the latter receiving L-Arginine to induce pancreatitis followed by Tirzepatide administration.
Results:
L-Arginine significantly elevated serum amylase, lipase, and inflammatory mediators (IL-6, IL-4, and IL-10), alongside oxidative stress markers and histopathological deterioration. Conversely, the L-Arginine + Tirzepatide group exhibited reduced lipase and IL-6 levels, suppressed reactive oxygen species (ROS) generation, and enhanced anti-inflammatory cytokines IL-4 and IL-10. Histopathological analysis revealed reduced necrosis and tissue damage in the L-Arginine + Tirzepatide group compared to the L-Arginine group, indicating Tirzepatide's possible protective effects. Immunofluorescence studies further demonstrated increased p-Akt expression, supporting the role of Tirzepatide in cellular repair and recovery.
Conclusion:
These findings highlight Tirzepatide's ability to mitigate pancreatic damage through antioxidant and anti-inflammatory mechanisms, underscoring its potential as a pharmacological agent for acute pancreatitis.
Related Concept Videos
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...